Phase II Study of Olaparib and IV Vitamin C in Advanced Prostate Cancer

Inclusion Criteria

• Have advanced prostate cancer that continues to grow despite low testosterone levels.
• Have a PSA level of at least 1 ng/mL.
• Have a confirmed diagnosis of prostate cancer.
• Continue receiving hormone therapy to keep testosterone levels low.
• May be taking medications to protect bones.
• May have had multiple previous treatments, including certain chemotherapies.
• Be 18 years or older.
• Be in good overall health, able to perform daily activities with minimal restrictions.
• Be able to take oral medication and consider using a port for vitamin C administration.
• Have tried at least one other systemic treatment for prostate cancer.
• Have normal organ and bone marrow function based on recent blood tests.
• Men must agree to use effective birth control during and for six months after treatment.
• Understand and agree to participate in the study by signing a consent form.

Exclusion Criteria

• Have known mutations in specific DNA repair genes.
• Have active cancer spread to the brain or spinal cord.
• Have previously used olaparib or similar drugs.
• Have had major surgery or certain cancer treatments recently.
• Need chemotherapy or radiation for pain relief soon.
• Use certain medications that interact with the study drugs.
• Have significant heart disease or uncontrolled medical conditions.
• Have other active cancers unless treated and disease-free for over five years.
• Have persistent side effects from previous cancer treatments.
• Have blood disorders like myelodysplastic syndrome or leukemia.
• Have difficulty swallowing pills or absorbing oral medications.
• Have active hepatitis or have had certain types of transplants.
• Have allergies to olaparib or its ingredients.